

31. (New) A method for identifying a compound that inhibits Breast Cancer Resistance Protein (BCRP) comprising:

- a) exposing cells which express BCRP to an agent transported by BCRP in the presence or absence of said compound;
 - b) measuring the intracellular level of said agent in said cells; and
 - c) comparing the intracellular level of said agent in said cells in the presence of said compound to the level of said agent in said cells in the absence of said compound,
- wherein an increase in the accumulation of said agent in said cells treated with said agent in the presence of said compound is an indication that said compound inhibits BCRP.

32. (New) The method of Claim 31, wherein said cells are selected from the group consisting of MCF-7/AdrVp cells, colon carcinoma S1 cells, HT29 cells, gastric carcinoma EPG85-257 cells, fibrosarcoma EPR86-079 cells, and myeloma 8226 cells.

33. (New) The method of claim 31, wherein said agent is selected from the group consisting of mitoxantrone, daunorubicin, and doxorubicin.

34. (New) A method for identifying a compound that inhibits Breast Cancer Resistance Protein (BCRP) comprising:

- a) exposing cells expressing BCRP to the fluorescent aza-anthrapyrazole BBR3390 in the present or absence of said compound;
- b) measuring the intracellular level of BBR3390 in said cells; and

c) comparing the intracellular level of BBR3390 in said cells in the presence of said compound to the level of BBR3390 in said cells in the absence of said compound,

wherein an increase in the accumulation of BBR3390 in said cells treated with BBR3390 in the presence of said compound is an indication that said compound inhibits BCRP.

35. (New) The method of claim 34, wherein said cells are selected from the group consisting of MCF-7/AdrVp cells, colon carcinoma S1 cells, HT29 cells, gastric carcinoma EPG85-257 cells, fibrosarcoma EPR86-079 cells, and myeloma 8226 cells.

*B¹
correl*

36. (New) The method of claim 29, wherein said compound is the compound of claim 31 or claim 34.

37. (New) The method of claim 29, wherein said compound is selected from the group consisting of an antibody to BCRP, an antisense RNA to BCRP, Fumitremorgin C, the compound of claim 31, and the compound of claim 34.
